AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02419391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA BN RSV
Description: Liquid frozen suspension of MVA-mBN294B
Study NCT02419391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tris Buffered Saline, sterile
Study NCT02794506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
Study NCT02794506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
Study NCT01473225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie information
Description: Nutrition label featuring calorie information will be provided.
Study NCT04561947 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Concentrated growth factor membrane
Description: Intravenous blood samples were collected in without anticoagulant 10-mL tubes and immediately centrifuged in a CGF centrifuge machine using a program with the following features: 30 ̋ acceleration, 2 min at 2700 rpm, 4 min at 2400 rpm, 4 min at 2700 rpm, 3 min at 3000 rpm, and 36 ̋ deceleration and stop. After centrifugation, four layers were formed in the tube: the serum layer at the top, the second buffy coat layer, the third CGF layer containing GF and unipotent stem cells, and the red blood cell layer at the bottom. The resulting CGF was removed from the tube and separated from the red blood cell layer using microsurgical scissors.
Study NCT03338439 — intervention group
Intervention type: DEVICE
Intervention: CSII
Description: This retrospective, observational trial will evaluate 104 diabetic patients with prior treatment with MDI initiating CSII therapy compared to 109 diabetic patients continuing MDI.
Study NCT00412607 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NAVISTAR® THERMOCOOL® Catheter
Description: The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
Study NCT01804868 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: case vignette tutorial
Description: The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
Study NCT01804868 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: passive web presentation on research regulation
Description: The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
Study NCT02902159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BWW Online Peer Support
Description: Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
Study NCT02902159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NHS Moodzone Online Information
Description: Directed to access to online information from NHS Moodzone
Study NCT02968615 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
Study NCT03185884 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: control carbohydrate blend
Study NCT03185884 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: experimental carbohydrate blend
Study NCT02165553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hibiscus sabdariffa calyces extract as a cold drink
Study NCT02165553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Hibiscus sabdariffa calyces extract as a cold drink
Study NCT00653731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Snoezelen ©
Description: Nursing individual intervention one time a week for 20 minutes
Study NCT00653731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: structured reminiscence therapy
Description: Individual nursing intervention: one time a week 20 minutes
Study NCT00653731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10-minutes activation
Description: Individual nursing intervention: two times a week for 10 minutes
Study NCT00653731 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured verbal communication
Description: Individual nursing intervention: one time a week for 20 minutes
Study NCT02693197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA
Description: A single oral dose of 448 mg
Study NCT04608838 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JTR-161
Description: JTR-161 (1 or 3 × 10\^8 cells/subject) will be suspended and administered in an intravenously infusion.
Study NCT04608838 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be suspended and administered in an intravenously infusion.
Study NCT03843099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Weight Loss + Future Thinking
Description: Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
Study NCT03843099 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss + Healthy Thinking
Description: Participants will receive a 4-week behavioral weight loss intervention based on evidence-based weight loss strategies focused on diet, exercise, and behavioral skills.
Study NCT00762476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3804-250A
Description: * topical product~* apply 2 pumps~* apply at least every 4 hours or after hand washing
Study NCT00762476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3804-291
Description: * topical~* apply 2 pumps~* apply at least every 4 hours or after hand washing
Study NCT05443113 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis
Description: Genetic analysis by geneticists
Study NCT03878329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: remote home monitoring
Description: Will use telemedicine to guide behavior changes in outcomes
Study NCT01645306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single intravenous injection
Study NCT04469608 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: Traditional Chinese medicine clinical daycare
Study NCT02370407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)
Description: 10 repetitions of practice on laparoscopic simulator.
Study NCT02370407 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mimic da Vinci robotic simulator
Description: 10 repetitions of practice on Mimic da Vinci robotic simulator.
Study NCT03770923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rupatadine
Description: Rupatadine 10 mg daily
Study NCT03770923 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 10 mg daily
Study NCT02563509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV-specific CD8 cells
Description: Based on HAART, receive HIV-specific CD8 cells transfuion.
Study NCT03923036 — intervention group
Intervention type: DRUG
Intervention: Antineoplastic Agents
Description: Exposure measurement to any anticancer drug in its therapeutic use for the metastatic colorectal cancer with its posology and duration (the list provided is non-limitative). Exposure to anticancer drugs for another indication than the colorectal cancer will also be collected.
Study NCT04752436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supra high intensity interval training
Description: The exercise program will consist of eight 20-second all-out exercise bouts followed by 10 seconds of rest for a total of 4 minutes of total exercise duration. The intensity of exercise is all out. The exercise will be conducted 3 times a week for 8 weeks.
Study NCT02204371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
Study NCT02204371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
Study NCT04016636 — intervention group
Intervention type: OTHER
Intervention: Standard of Care
Description: Participants in this observational study with confirmed diagnosis of CLL receiving ibrutinib in routine clinical practice settings will be observed approximately for 12 months.
Study NCT05705713 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: chest computed tomography (CT)
Description: Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
Study NCT05705713 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: chest computed tomography (CT)
Description: Within the first 12 hours of suspected inhalation lung injury, fiberoptic bronchoscopy was done to confirm the diagnosis. After confirming the diagnosis, an initial chest CT in the first 24 hrs through which the radiologist score (RADS) together with bronchial wall thickening (BWT) was done.
Study NCT00619632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lactation Consultant
Description: Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
Study NCT00619632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Prompt
Description: Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
Study NCT00619632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LC+ Provider Prompt
Description: Participants in this group receive both the LC and Provider Prompt interventions.
Study NCT03864588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
Study NCT03864588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: For primary TKA, Ropivacaine is used in both arms, either performed intra-operatively by surgeon or post-operatively (ultrasound guided) by anesthesiologist.
Study NCT01697722 — intervention group
Intervention type: DRUG
Intervention: Extra-fine hydrofluoroalkane-beclometasone dipropionate
Description: Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
Study NCT01697722 — intervention group
Intervention type: DRUG
Intervention: ICS / LABA via separate pMDI and / or BAI inhalers
Description: A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
Study NCT02185612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Savings program
Description: The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
Study NCT01690936 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almonds 43g/day
Description: 43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
Study NCT03493126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: 17β-estradiol vaginal cream
Study NCT03493126 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Compounded placebo cream
Study NCT02737215 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: patients will receive CPAP therapy with Auto-CPAP
Study NCT00612326 — intervention group
Intervention type: PROCEDURE
Intervention: MRI and PET scanning procedures
Description: a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
Study NCT00967642 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Insulin
Description: continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
Study NCT04000321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Windmill at 30 Minutes
Description: The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
Study NCT04000321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Windmill at 45 Minutes
Description: The so-called windmill technique of placenta development for the management of the retained placenta involves the application of a continuous 360-degree umbilical traction force with centripetal rotation in such a way that it runs at the level of the introitus perpendicular to the direction of the birth canal. This rotation around a 360-degree traction plane is repeated slowly and continuously with a motion that resembles the motion of the wings of a windmill until the placenta can be safely delivered.
Study NCT04704609 — intervention group
Intervention type: OTHER
Intervention: Standard of Care Imaging
Description: We are collecting imaging that is standard of care for uveitis patients
Study NCT02649283 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: OrbiSymm device
Description: Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
Study NCT02649283 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast symmetrisation
Description: Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
Study NCT00368966 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Study NCT00368966 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal Conjugate Vaccine
Study NCT03987152 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Daily intake of Sirolimus during Challenge and Rechallenge phase
Study NCT00506909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID
Study NCT00506909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 IU BID or 40 IU BID
Study NCT01495377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
Study NCT01495377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
Study NCT01495377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium
Description: 37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
Study NCT01495377 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamometer (Jamar)
Description: portable hydraulic hand dynamometer to assess grip strength.
Study NCT00748293 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Low-residue diet
Description: Commercialized (not yet marketed)low-residue diet
Study NCT01111110 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-static then static
Description: Albuterol using static chambers
Study NCT01473225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No calorie information
Description: No nutrition label will be provided in this condition.
Study NCT02741232 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% with epinephrine 1/400000
Study NCT02741232 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham block
Study NCT01183416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 monoclonal antibody and 13-cis-Retinoic Acid
Description: A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
Study NCT04753333 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electromyography biofeedback (EMG-BF)
Description: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
Study NCT04340934 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REZUM system
Description: Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
Study NCT04753333 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham electromyography biofeedback (EMG-BF)
Description: Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
Study NCT00305565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 0.25 milliamps (mA)
Study NCT00305565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 0.5-1.0 mA
Study NCT00305565 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 1.0-1.5 mA
Study NCT03043963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Lengthen the duration of sleep time.
Study NCT03043963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Timing
Description: Regularize the timing of the sleep period.
Study NCT00812500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
Study NCT03600025 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Typbar-TCV vaccine
Description: vaccine will receive intramuscularly
Study NCT06545461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables (F+V)
Description: Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups daily of F+V provided in weekly allotments. Amount provided will be that calculated for the participant multiplied times number of household members to assure participants eat the prescribed amount and do not share with household members.
Study NCT06545461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3)
Description: Participants will receive 0.3 mEq/kg bw/day NaHCO3 tablets to match the alkali provided by F+V given to F+V participants. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in two divided oral doses.
Study NCT06545461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive standard medical care but no additional alkali (F+V nor NaHCO3).
Study NCT03104010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin Injection
Description: Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.